CutisPharma, a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, announced today that it is entering into Active Pharmaceutical Ingredient (API) supply and joint development agreements with Dr. Reddy’s Laboratories Ltd. to advance several programs in CutisPharma’s R&D portfolio, including RM-02, RM-03, and RM-06, toward FDA approval.
“This partnership has significant strategic benefits for both parties,” said Neal Muni, MD, MSPH, Chief Executive Officer of CutisPharma. “Dr. Reddy’s Laboratories breadth of expertise and international infrastructure provide great synergy to CutisPharma’s own R&D and commercial organizations and will be a significant catalyst in our plans to fast-track the development of three of our programs towards New Drug Application (NDA) filings.”
Deepak Sapra, Vice President & Global Head, CPS Business of Dr. Reddy’s Laboratories, said “we continuously engage in research to find innovative solutions that address the unmet needs of patients and to create a robust healthcare ecosystem. The partnership with CutisPharma will further enhance and strengthen their R&D portfolio in bringing good health to millions in the country.”
“By leveraging the strengths of both parties, we look forward to expediting the development of three of our key R&D portfolio assets and maximizing commercial value of these programs in the United States as well as select international markets.” Muni said.
CutisPharma has aggressively invested in its research and development pipeline, recently announcing the opening of a state-of-the-art manufacturing center at its Wilmington, Mass., facility and completion of validation activities supporting its first NDA filing of the Company’s lead pipeline drug, RM-01, next year. The partnership with Dr. Reddy’s Laboratories will allow for the acceleration of three additional drugs, RM-02, RM-03 and RM-06, towards FDA approval.
As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.
McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.
AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.